| [1] |
Chan KY, Wang W, Wu JJ, et al. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990～2010: a systematic review and analysis[J].The Lancet, 2013, 381(9882): 2016-2023.
|
| [2] |
Weuve J, Hebert LE, Scherr PA, et al. Prevalence of Alzheimer disease in US states[J]. Epidemiology, 2015, 26(1): e4-e6.
|
| [3] |
Burns A, Iliffe S. Alzheimer's disease[J]. BMJ, 2009, 338: b158.
|
| [4] |
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment[J]. Journal of the American Geriatrics Society, 2005, 53(4): 695-699.
|
| [5] |
Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014[J]. Journal of internal medicine, 2014, 275(3): 251-283.
|
| [6] |
Use, C.f.M.P.f.H., Guideline on medicinal products for the treatment of Alzheimer's Disease and other dementias (Doc. Ref. CPMP/EWP/553/95 Rev. 1). London, European Medicines Agency, 2008.
|
| [7] |
关亮．治疗阿尔茨海默病药物临床试验技术指导原则[J]．中国现代医生，2007，45(11Z): 72-75.
|
| [8] |
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria[J]. The Lancet Neurology, 2014, 13(6): 614-629.
|
| [9] |
Frisoni GB, Winblad B,O'Brien JT. Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready forwidespread clinical use[J]. International Psychogeriatrics, 2011, 23(8): 1191-1196.
|
| [10] |
Pharmaceutical Research and Manufacturers of America. ResearchingAlzheimer's Medicines:Setbacks and Stepping Stones, 2012. [2016-01-15].
URL
|
| [11] |
Arrighi HM, Neumann PJ, Lieberburg IM, et al. Lethality of Alzheimer's disease and its impact on nursing home placement[J].Alzheimer Dis Assoc Disord, 2010, 24(1): 90-95.
|
| [12] |
彭丹涛，许贤豪，刘江红，等．简易智能精神状态检查量表检测老年期痴呆患者的应用探讨[J]．中国神经免疫学和神经病学杂志，2005，12(4): 187-190.
|